CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of neuroendocrine tumors.
  
  LEARNING OBJECTIVES

  • Appreciate the variability in clinical presentation, pace of growth and prognosis of different anatomical subtypes of neuroendocrine tumors (NETs), and evaluate how these and other patient- and disease-related factors affect the selection and sequencing of systemic treatment for unresectable or metastatic forms of the disease.
  • Review published research findings supporting the use of somatostatin analogs (SSAs) for patients with advanced NETs in order to optimally incorporate these agents into current clinical management algorithms.
  • Assess the biological rationale for combining SSAs with peptide receptor radionuclide therapy for patients with newly diagnosed, somatostatin receptor-positive advanced NETs, and consider how published Phase III efficacy results may establish the clinical role of this novel treatment strategy.
  • Evaluate available research findings with peptide receptor radionuclide therapy in the management of progressive NETs in order to optimally integrate this therapeutic approach into current treatment algorithms.
  • Appraise available clinical trial data evaluating multikinase inhibitors for previously treated advanced NETs, and counsel patients regarding the risks and benefits of these novel agents.
  • Appraise the documented prevalence of von Hippel-Lindau-associated NETs, and develop strategies to care for patients with this unique manifestation of the disease.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/InsideTheIssue2024/Presentations/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Pamela Kunz, MD
  Associate Professor of Medicine/Oncology
  Division Chief, GI Oncology
  Director, Center for GI Cancers
  Yale School of Medicine and Yale Cancer Center
  New Haven, Connecticut
  
  Advisory Committees (All Uncompensated): Exelixis Inc, Novartis, RayzeBio; Contracted Research: Novartis, RayzeBio; Speaker: Bristol Myers Squibb, Foundation Medicine.
  
  Simron Singh, MD, MPH
  Professor, University of Toronto
  Susan Leslie Clinic for Neuroendocrine Tumours
  Odette Cancer Centre
  Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada
  
  Advisory Committees: Ipsen Biopharmaceuticals Inc, Novartis.
  
  SURVEY PARTICIPANTS — Daniel M Halperin, MD — Advisory Committees: Amryt Pharma, Camurus, Crinetics Pharmaceuticals, Exelixis Inc, Harpoon Therapeutics, ITM Isotope Technologies Munich SE, Lantheus, Novartis; Contracted Research: Camurus, ITM Isotope Technologies Munich SE, Novartis, RayzeBio; Data and Safety Monitoring Board/Committee: RadioMedix Inc. Daneng Li, MD — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Coherus BioSciences, Delcath Systems Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Merck, Sumitomo Dainippon Pharma Oncology Inc, TransThera Sciences, TriSalus Life Sciences; Speakers Bureau: Ipsen Biopharmaceuticals Inc. Heloisa P Soares, MD, PhD — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Novartis; Contracted Research: Bristol Myers Squibb, ITM Isotope Technologies Munich SE, Novartis. Jonathan Strosberg, MD — Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc; Contracted Research: ITM Isotope Technologies Munich SE, RadioMedix Inc, RayzeBio.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Exelixis Inc, Merck, and Novartis.
  
  Release date: September 2024
  Expiration date: September 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.